PhoreMost
Drugging the Undruggable
- Website
- phoremost.com
- Total Funding
- $12.0M
- Last Round
- $12.0M Extension RoundSep 2024
- Rounds
- 1
About
PhoreMost is a Cambridge-based biotechnology company developing cancer therapies against difficult-to-drug disease targets. Its lead program, PMC-001, is an orally bioavailable, central-nervous-system-penetrant microtubule disruptor being evaluated for primary and metastatic brain cancers. The company also advances discovery-stage programs through its targeted protein-degradation and mini-protein engineering platforms.
Summary
PhoreMost is a Biotech company. It has raised $12.0M in total across 1 round, most recently a $12.0M Extension Round round in Sep 2024. Investors include Astellas Venture Management.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sep 2024
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/phoremost"><img src="https://indexed.vc/api/badge/company/phoremost" alt="PhoreMost on Indexed.vc" width="260" height="76" /></a>